Eden Research plc (AIM:EDEN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 17.79M +9.3% |
| Revenue (ttm) | 3.62M -8.1% |
| Net Income | -2.35M |
| EPS | -0.00 |
| Shares Out | 613.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 257,599 |
| Average Volume | 425,752 |
| Open | 3.000 |
| Previous Close | 2.900 |
| Day's Range | 2.800 - 3.000 |
| 52-Week Range | 1.960 - 5.000 |
| Beta | 1.67 |
| RSI | 23.55 |
| Earnings Date | May 6, 2026 |
About Eden Research
Eden Research plc, together with its subsidiaries, engages in the development and sale of biopesticides in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and Cedroz brands for crop protection applications. It also provides consume products, such as head-lice treatment, deodorants, odour neutralizer, and fragrances, as well as food flavourings and active ingredients; and animal health products co... [Read more]
Financial Performance
In 2024, Eden Research's revenue was 4.30 million, an increase of 34.79% compared to the previous year's 3.19 million. Losses were -1.91 million, -70.64% less than in 2023.
Financial StatementsNews
AIM Market Roundup: Zenova, CAP-XX, Eden Research
Zenova, CAP-XX, Eden Research are today's top risers, while Revolution Beauty, Arkle Resources take the biggest fall on London's AIM market